Tesamorelin (10 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency is once nightly by subcutaneous injection for the duration of the cycle. Injecting 30 to 60 minutes before sleep aligns the growth hormone pulse with slow wave sleep architecture, and the fasted window of at least 2 hours matters because dietary carbohydrate and fat blunt the growth hormone response. Half life is short, roughly 8 minutes in healthy subjects and roughly 38 minutes at steady state in HIV patients, and subcutaneous bioavailability sits below 4%; the compound works through brief potent receptor activation rather than by lingering in circulation. A week 8 IGF-1 check is the critical decision point, with high normal as the target rather than supraphysiologic levels: if IGF-1 exceeds 350 to 400 ng/mL, the dose is reduced or moved to every other day. Rotate sites systematically; the love handles are often the best tolerated area and the lower abdomen the worst, and a deeper injection delivered slowly over 30 to 60 seconds reduces local reactions. The 12 to 16 week on and 2 to 4 week off structure is risk management for sustained IGF-1 elevation, edema, and glucose drift, not a withdrawal requirement; longer continuous use belongs in a clinician managed plan with regular labs.

Results Timeline

Sequence described in the research record. Individual response varies.

• Weeks 1 to 4: titration at 1 mg nightly. Injection reactions are minimal through week 3.
• Weeks 4 to 5: first histamine welts typically appear. This is progressive mast cell sensitization, not technique failure.
• Weeks 5 to 16: standard 2 mg nightly, with consistent injection site reactions from week 6 onward.
• Week 8: IGF-1 recheck, the decision point for holding the dose, reducing to 1 mg, or moving to every other day.
• End of cycle: 2 to 4 weeks off before repeating. Visceral fat regain begins once dosing stops, so the protocol is an ongoing intervention rather than a reset.

Reconstitution Steps

1. Use isotonic bacteriostatic water (0.9% sodium chloride); it significantly reduces both injection sting and the progressive histamine welt reactions common with tesamorelin.
2. Draw 1.0 mL isotonic bacteriostatic water with a sterile syringe.
3. Inject slowly down the vial wall; avoid foaming.
4. Gently swirl until dissolved (do not shake).
5. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light, and use within 28 days. At 10 mg/mL, 1 unit = 0.01 mL » 100 mcg on a U-100 insulin syringe, so 1 mg is 10 units (0.10 mL) and 2 mg is 20 units (0.20 mL).

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at minus 20 °C (minus 4 °F) in dry, dark conditions; stable for at least 12 months.
• Reconstituted: refrigerate at 2 to 8 °C (35.6 to 46.4 °F), use within 28 days, and avoid freeze thaw cycles.

• Allow vials to reach room temperature before opening to reduce condensation uptake.
• Protect from light at all times; keep vials in the original carton or another opaque container.

Supplies Needed

Planning math is based on a course of 12 weeks at an average nightly dose of 1.5 mg, which works out to 10.5 mg per week.

Peptide Vials (Tesamorelin, 10 mg vial):

• A course of 12 weeks at 1.5 mg nightly totals 126 mg, roughly 13 vials of 10 mg each; a course of 16 weeks at 2 mg nightly totals 224 mg, roughly 23 vials.

Insulin Syringes (U-100):

• Per week: 7 U-100 insulin syringes, one per night, with 50 unit barrels preferred for accuracy at these small volumes.
• Full course of 12 weeks: 84 syringes, or roughly 250 per year across two cycles.

Bacteriostatic Water (10 mL bottles):

• At 1.0 mL of isotonic bacteriostatic water (0.9% sodium chloride) per 10 mg vial, one 10 mL bottle covers 10 vials, so a course of 12 weeks takes about 2 bottles.

Alcohol Swabs:

• Per injection: 2 alcohol swabs, one for the vial stopper and one for the skin.
• Full course of 12 weeks: 168 swabs, or roughly 500 per year, which is 5 boxes of 100.

Important Notes

Practical considerations for consistency and safety.

• Injection reactions are histamine mediated rather than a pH burn, and they develop progressively: minimal in weeks 1 to 3, first welts in weeks 4 to 5, consistent reactions from week 6 onward. This is mast cell sensitization, not a technique problem, and it is specific to tesamorelin in a way it is not for most other peptides.
• An H1 antihistamine taken 30 to 60 minutes before injection, such as cetirizine 10 mg or loratadine 10 mg, reduces welt severity by 50 to 70% for most users. Diphenhydramine 25 mg is an option when injecting at bedtime and sedation is welcome. Deeper injection with a half inch needle at 90 degrees, a firmly pinched fat pad, slow delivery over 30 to 60 seconds, and site rotation all help further.
• Visceral fat returns after stopping. Phase III extension data recorded 24.5% visceral fat regain by week 52 in patients who stopped at week 26, nearly erasing six months of benefit. Tesamorelin adjusts the metabolic set point while it is in use; the body does not learn a new baseline.
• Baseline IGF-1, fasting glucose, HbA1c, and a lipid panel are taken before starting, with an IGF-1 recheck at week 8. Growth hormone is inherently diabetogenic, so periodic glucose labs matter most where insulin resistance, prediabetes, or type 2 diabetes is present. Fluid retention, puffy fingers, and mild carpal tunnel tingling are a dose related class effect that resolves with dose reduction; persistent or severe tingling is a reason to hold and reassess.
• Absolute contraindications are active malignancy or a history of cancer, proliferative diabetic retinopathy, pregnancy or breastfeeding, and pituitary disorders. Relative contraindications are uncontrolled diabetes, severe insulin resistance, and severe cardiovascular disease. Common stacking partners in the research literature include GLP-1 agonists, AOD-9604, DSIP, BPC-157 with TB-500, and Ipamorelin at 200 to 500 mcg added after 4 weeks when the response to tesamorelin alone is slow.
• Regulatory Note: FDA approved in 2010 as Egrifta for lipodystrophy associated with HIV, the strongest evidence base in the growth hormone secretagogue class; any use outside that indication is off label. The approved EGRIFTA SV dose is 1.4 mg per 0.5 mL, which is not the same as research vial convention and should not be conflated with it. Tesamorelin is WADA prohibited and testing detects its metabolites, so athletes subject to doping control fall outside this protocol entirely.

How This Works

Tesamorelin binds GHRH receptors on somatotrophs in the anterior pituitary and triggers the cAMP and PKA cascade that drives growth hormone synthesis and release. The trans-3-hexenoic acid modification at the N terminus shields the molecule from DPP-IV, the enzyme that degrades native GHRH within minutes, giving a modestly longer working window; even so, half life stays short at roughly 8 minutes in healthy subjects and roughly 38 minutes at steady state in HIV patients, and subcutaneous bioavailability sits below 4%. The effect therefore comes from brief potent receptor activation rather than from circulating drug. The downstream cascade runs in four steps: pituitary activation produces a burst of growth hormone that mimics the natural nocturnal pulse; that growth hormone reaches liver and peripheral tissue and stimulates IGF-1, which mediates most of the downstream effects on muscle, fat, and tissue repair; a metabolic shift toward lipolysis follows, concentrated in visceral adipose tissue where growth hormone receptor density is higher than in subcutaneous fat, alongside nitrogen retention and protein synthesis in muscle; and somatostatin feedback engages as growth hormone and IGF-1 rise, placing a physiologic ceiling on further release. That feedback brake is what separates tesamorelin from recombinant human growth hormone, which bypasses the pituitary entirely and can produce sustained supraphysiological levels, and it makes supraphysiological spikes mechanically difficult here. Visceral specificity is not a targeting property of the molecule; visceral adipocytes are simply more responsive to growth hormone stimulated lipolysis than subcutaneous ones. Connective tissue repair consolidation happens during slow wave sleep when growth hormone pulses fire, and tesamorelin amplifies that existing signal rather than replacing it. The welt reaction at injection sites is mast cell mediated rather than pH related, with sensitization building progressively over weeks 4 to 8 of consistent use.

Benefits & Side Effects

Observations from the published record.

• LIPO-010 Phase III (n=412): visceral adipose tissue fell 19.6% versus placebo at 26 weeks on 2 mg daily subcutaneous, 95% CI 15.3% to 23.7%, with waist circumference down 1.8 cm versus placebo and IGF-1 up 106 to 109 ng/mL.
• CTR-1011 Phase III (n=404): visceral adipose tissue fell 11.7% versus placebo at 26 weeks on the same dose, 95% CI 7.1% to 16.2%, with waist circumference down 1.3 cm and improved triglycerides.
• Extension from 26 to 52 weeks: continued treatment added a further 1.4% visceral reduction and maintained benefit, while the group switched to placebo regained 24.5% of visceral fat by week 52. The difference between groups was 25.8% (P=0.0008).
• The effect is depot specific, with minimal change in subcutaneous fat, which makes it the metabolically relevant fat depot for insulin resistance, cardiovascular disease, and NAFLD. In HIV NAFLD, an MRI confirmed randomized trial showed reduced hepatic fat fraction and improved histologic features on biopsy, including reduced steatosis and slowed fibrosis progression. A dedicated type 2 diabetes safety trial showed no major worsening of HbA1c or fasting glucose.
• Side effects from the Phase III safety profile: injection site reactions in 30 to 51% versus 21 to 24% on placebo, myalgia in 4 to 8% versus 2%, and fluid retention in 5 to 10% versus 1 to 6%, with serious adverse event rates similar to placebo. No malignancy signal appeared in trial windows up to 52 weeks, no cardiovascular event signal appeared, and no liver toxicity was seen; IGF-1 elevation remains the theoretical concern and active cancer stays an absolute contraindication.
• What tesamorelin does not do: it does not produce dramatic scale weight loss, since the effect is depot specific rather than generalized; it does not replace dietary and training discipline; it does not deliver permanent fat loss; and it does not suppress the HPTA, which separates it from exogenous testosterone and anabolic steroids. All rigorous evidence comes from lipodystrophy associated with HIV, so general body composition, longevity, and recomposition applications are extrapolations from that base.

Lifestyle Factors

Complementary strategies for best outcomes.

• Eat at least 2 hours before injection. Post meal free fatty acids and glucose blunt the growth hormone response, evening carbohydrate spikes blunt the pulse further through insulin, and alcohol within 4 hours of injection suppresses growth hormone secretion.
• Sleep 7 to 9 hours. The protocol assumes adequate slow wave sleep as its substrate, and sleep debt directly undermines the pulse the peptide amplifies; DSIP is a common pairing where sleep is fragmented.
• Train with resistance 3 to 4 times weekly and take in 1.6 to 2.2 g of protein per kg of body weight daily. Tesamorelin supplies the hormonal signal while mechanical load and protein supply the substrate, and this matters most during GLP-1 stacking when overall intake is suppressed.
• Track labs and fluid status: IGF-1 at week 8, fasting glucose and HbA1c at baseline and during cycles, and adequate hydration and electrolytes to reduce edema risk from growth hormone driven sodium and water retention.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol swabs; allow to air-dry completely.
2. Pinch a skinfold at the injection site (abdomen preferred, at least 2 inches from navel).
3. Insert the needle at 90 degrees (if adequate subcutaneous fat) or 45 degrees (if lean).
4. Release the pinch, then inject slowly; wait 2 to 3 seconds before withdrawing.
5. Rotate injection sites systematically (left/right abdomen, thighs, upper arms) to prevent lipohypertrophy.
6. Dispose of used syringes immediately in a puncture-proof sharps container.

References

Source citations for further reading.

1. Falutz J et al. GHRH metabolic effects in HIV (NEJM, 2007).
2. Falutz J et al. Tesamorelin pooled Phase III analysis, n=816 (J Clin Endocrinol Metab, 2010).
3. CADTH Clinical Review Report: Tesamorelin, Egrifta (CADTH, 2016).
4. Stanley TL et al. Tesamorelin visceral and liver fat in HIV NAFLD (Lancet HIV, 2019).
5. Bedimo R. GH and tesamorelin in lipodystrophy associated with HIV (HIV/AIDS Res Palliat Care, 2011).
6. Clemmons DR et al. Safety of tesamorelin in T2D patients (PLOS One, 2017).